9 months ago
NBIX
AnalystsAndrew S. FeinAndrew S. Fein's Stock Forecasts
AnalystsAndrew S. Fein
Analyst Ranking
Top 11%
#570 out of 5556 analysts
Average Return
+16.83%
Win Rate
60%48 out of 80
Risk vs Reward
Poor
Good
Andrew S. Fein's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Day One Biopharmaceuticals IncDAWN | +271.21% | $5.80 | $21.53 | 2025-08-06 - 2026-04-23 | Buy |
Palvella Therapeutics IncPVLA | +230.08% | $47.30 | $156.13 | 2025-08-15 - 2026-08-14 | Buy |
Palvella Therapeutics IncPVLA | +153.20% | $57.69 | $146.07 | 2025-09-25 - 2026-09-24 | Buy |
Immunovant IncIMVT | +142.68% | $16.12 | $39.12 | 2025-09-04 - 2026-09-03 | Buy |
Kymera Therapeutics IncKYMR | +131.59% | $51.16 | $118.48 | 2025-09-18 - 2026-09-17 | Buy |
Andrew S. Fein Analyst Color
Get additional color on Andrew S. Fein's coverage of popular stocks
a year ago
BCRX
Andrew S. Fein's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Alector IncALEC | 2 | Buy | $8.00 | +249.34% | Maintains | 25 days ago |
Liquidia CorpLQDA | 8 | Buy | $65.00 | +46.40% | Maintains | 25 days ago |
Insmed IncINSM | 5 | Buy | $220.00 | +92.29% | Reiterates | a month ago |
Palvella Therapeutics IncPVLA | 7 | Buy | $246.00 | +39.84% | Maintains | a month ago |
Amylyx Pharmaceuticals IncAMLX | 4 | Buy | $55.00 | +86.44% | Maintains | 3 months ago |
Biogen IncBIIB | 3 | Buy | $251.00 | +1.07% | Maintains | 3 months ago |
Metavia IncMTVA | 5 | Buy | $20.00 | +1,298.60% | Reiterates | 4 months ago |
Biocryst Pharmaceuticals IncBCRX | 2 | Buy | $32.00 | +316.12% | Maintains | 4 months ago |
Fulcrum Therapeutics IncFULC | 4 | Hold | $3.00 | -18.92% | Downgrades | 5 months ago |
Catalyst Pharmaceuticals IncCPRX | 1 | Hold | $31.50 | +0.03% | Downgrades | 5 months ago |
Wave Life Sciences IncWVE | 5 | Buy | $13.00 | +286.33% | Maintains | 6 months ago |
Madrigal Pharmaceuticals IncMDGL | 4 | Buy | $620.00 | +55.14% | Reiterates | 6 months ago |
Kalvista Pharmaceuticals IncKALV | 1 | Hold | $27.00 | 0.00% | Downgrades | 6 months ago |
Aura Biosciences IncAURA | 1 | Buy | $24.00 | +265.85% | Maintains | 6 months ago |
Protara Therapeutics IncTARA | 1 | Buy | $27.00 | +1,073.91% | Maintains | 6 months ago |
Neurocrine Biosciences IncNBIX | 3 | Buy | $215.00 | +30.60% | Maintains | 7 months ago |
United Therapeutics CorpUTHR | 3 | Buy | $660.00 | +17.43% | Maintains | 7 months ago |
Denali Therapeutics IncDNLI | 1 | Buy | $42.00 | +109.27% | Maintains | 7 months ago |
Vertex Pharmaceuticals IncVRTX | 4 | Buy | $641.00 | +17.17% | Maintains | 8 months ago |
Savara IncSVRA | 3 | Buy | $10.00 | +107.04% | Maintains | a year ago |
Dbv Technologies SaDBVT | 3 | Buy | $40.00 | +282.78% | Maintains | a year ago |
Kymera Therapeutics IncKYMR | 3 | Buy | $134.00 | +1.72% | Maintains | a year ago |
Kamada LtdKMDA | 1 | Buy | $13.00 | +79.81% | Maintains | a year ago |
Arcturus Therapeutics Holdings IncARCT | 3 | Hold | $9.00 | -13.04% | Maintains | a year ago |
Prothena Corp Public Ltd CoPRTA | 3 | Buy | $30.00 | N/A | Maintains | a year ago |
Akero Therapeutics IncAKRO | 2 | Hold | $54.00 | N/A | Downgrades | a year ago |
89bio IncETNB | 2 | Hold | $14.50 | N/A | Downgrades | a year ago |
Terns Pharmaceuticals IncTERN | 1 | Hold | $7.44 | N/A | Assumes | a year ago |
Immunovant IncIMVT | 1 | Buy | $35.00 | N/A | Reiterates | a year ago |
Arvinas IncARVN | 1 | Buy | $18.00 | N/A | Maintains | a year ago |
Day One Biopharmaceuticals IncDAWN | 1 | Buy | $25.00 | N/A | Maintains | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.